Cisbio extend the Kinase platform and present the latest application of IP-One HTRF^®

Cisbio's HTRF® KinEASE™ platform has expanded to include a universal assay for tyrosine kinases. The HTRF KinEASE TK assay is based on our patented HTRF technology and uses a unique tyrosine peptide substrate in combination with a Europium-labeled monoclonal antibody. The HTRF KinEASE™ TK assay has been validated on 59 tyrosine kinases to-date including both receptor and cytoplasmic TKs. A proprietary substrate stabilizing buffer (SEB) enhances assay performance, enables the use of lower enzyme concentrations, while maintaining inhibitor properties such as IC50s.

A new secondary messenger for Gq coupled receptor investigation.Cisbio’s IP-One assay, based on its proprietary HTRF® technology, is the first HTS immunoassay that can easily detect inositol(1)phosphate (IP1), a stable second messenger which tightly correlates with Gq-coupled receptor activity. This assay displays all the characteristic advantages of an HTRF® system: totally homogeneous, detection via fluorescence, signal stability, miniaturization down to uHTS levels (less than 10 µl), "mix & measure" type protocols limited to just a few dispensing steps, and use in "single plate" mode on cultured cells. IP-One has been validated in a wide variety of different situations: stable lines, transitory transfections, different cell types (CHO, HEK, 1321N1). The validations also conclusively demonstrated the assay’s performances in the presence of cell lines using Ga16 or Gqi9 type chimeric constructions. With IP-One and cAMP, Cisbio offers a reliable and functional platform for investigating and screening GPCR activity.